BCAX
Wall Street says “maybe buy it”
Bicara Therapeutics just got a consensus Moderate Buy from the analysts covering it, with an average 12-month price target of $28. That’s the market’s way of saying, “We’re not screaming from the rooftops, but we’re not exactly running away either.”
The stock’s already been on a little sprint
Shares opened at $22.98, up about 3.8%, and the stock’s sitting near the top of its $7.80 to $23.16 12-month range. So the market is already giving Bicara some credit — maybe more than it was a few months ago when the name was still wandering around in the bargain bin.
The catch: insiders are selling
Here’s the part investors usually squint at: insiders have sold 137,969 shares worth about $2.59 million over the past 90 days, including a March sale by the COO. That doesn’t automatically mean trouble — executives sell for all kinds of reasons — but it’s not exactly the same vibe as “we’re all-in and the future is beautiful.”
Why you should care
Analyst ratings can nudge sentiment, especially for a biotech name that lives and dies by narrative, cash burn, and pipeline hopes. But when the buy-side cheerleading comes with insider selling in the background, you’ve got to ask: is Wall Street seeing upside, or just painting a nicer story on a still-pricey stock?
Big picture: Bicara is getting the analyst love, but the stock still has to prove it deserves the applause.